Metabolic profiling reveals key metabolic features of renal cell carcinoma
Gareth Catchpole(Max Planck Institute of Molecular Plant Physiology), Steffen Weikert(St. Hedwig-Krankenhaus), Joachim Selbig(Max Planck Society), Cornelia Weikert(Federal Institute for Risk Assessment), Manfred Johannsen(Charité - Universitätsmedizin Berlin), Klaus Jung(University of Veterinary Medicine Hannover, Foundation), Alexander Platzer(University of Potsdam), Hans Krause(Charité - Universitätsmedizin Berlin), Lothar Willmitzer(Max Planck Society), Kurt Miller(Charité - Universitätsmedizin Berlin), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin)
Cited by 118
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
|International Journal of Cancer|2009|613